http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0235164-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29C48-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29C48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2967 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2962 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2938 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02B6-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02B6-4436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02B6-02033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B29C48-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B29C48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G02B6-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-54 |
| filingDate | 1986-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1990-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1990-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0235164-B1 |
| titleOfInvention | Imidazole analogs of mevalonolactone and derivatives thereof |
| abstract | Compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein R1 and R2 are alkyl not containing an asymmetric carbon atom, cycloalkyl, adamantyl-1 or possibly substituted phenyl, R3 is hydrogen, alkyl not containing an asymmetric carbon atom, cycloalkyl, adamantyl-1, styryl or possibly substituted phenyl, X is -(CH2)m-, -CH=CH-, -CH=CH-CH2- or -CH2-CH=CH-, wherein m is 0, 1, 2, or 3, and Z is formula (II) or formula (III) or with Ra is hydrogen and Rb is hydroxy, or CRaRb is formula (IV) or formula (V) wherein each R15 is primary or secondary alkyl not containing an asymmetric carbon atom, the two R15's being the same, or the two R15's taken together are -(CH2)q-, wherein q is 2 or 3, R13 is hydrogen or alkyl, and R14 is hydrogen, a physiologically acceptable ester group, or a pharmaceutically acceptable cation, with certain provisos and the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds. |
| priorityDate | 1985-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.